{"id":"venlafaxine-xr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sweating"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Hypertension"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased neurotransmitter concentrations in the synaptic cleft. The extended-release (XR) formulation provides sustained drug delivery over 24 hours, allowing for once-daily dosing. This dual mechanism is thought to enhance mood regulation and reduce anxiety and pain symptoms.","oneSentence":"Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:10.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07330648","phase":"PHASE2","title":"Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-10-10","conditions":"Generalized Anxiety Disorder","enrollment":216},{"nctId":"NCT04961190","phase":"PHASE4","title":"A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-05-25","conditions":"Posttraumatic Stress Disorder","enrollment":302},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT01114698","phase":"PHASE2","title":"A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-03","conditions":"Depression","enrollment":12},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT03574792","phase":"NA","title":"Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-05-03","conditions":"Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","enrollment":62},{"nctId":"NCT03588572","phase":"NA","title":"The Effect of Venlafaxine on Language Function in Patients With Subcortical Aphasia: A fMRI Study","status":"COMPLETED","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2018-08-01","conditions":"Subcortical Aphasia, Ischemic Stroke","enrollment":43},{"nctId":"NCT00354432","phase":"PHASE3","title":"Soy Protein/Effexor Hormone Therapy for Prostate Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2007-02-01","conditions":"Hot Flashes, Prostate Cancer","enrollment":120},{"nctId":"NCT00878748","phase":"PHASE4","title":"Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-04","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00644982","phase":"PHASE4","title":"A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-10","conditions":"Depressive Disorder, Major","enrollment":163},{"nctId":"NCT02637193","phase":"PHASE1","title":"A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2015-12","conditions":"Healthy Subjects","enrollment":54},{"nctId":"NCT00151450","phase":"PHASE3","title":"Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-03","conditions":"Anxiety","enrollment":390},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT04229602","phase":"NA","title":"Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-01-02","conditions":"Bioequivalence Study","enrollment":28},{"nctId":"NCT00186264","phase":"NA","title":"Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?","status":"COMPLETED","sponsor":"Stanford University","startDate":"2002-08","conditions":"Depressive Disorder, Major","enrollment":18},{"nctId":"NCT03522987","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Pilot Treatment Study","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05","conditions":"Anxiety, Depression, Epilepsy","enrollment":""},{"nctId":"NCT02181231","phase":"PHASE1, PHASE2","title":"Buprenorphine Used With Treatment Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-06-01","conditions":"Major Depressive Disorder, Depression","enrollment":18},{"nctId":"NCT00854100","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-06-30","conditions":"Major Depressive Disorder","enrollment":231},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT02263248","phase":"PHASE1, PHASE2","title":"Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2014-12","conditions":"Major Depressive Disorder, Depression","enrollment":56},{"nctId":"NCT00693849","phase":"PHASE4","title":"International Study to Predict Optimised Treatment - in Depression","status":"UNKNOWN","sponsor":"BRC Operations Pty. Ltd.","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":2688},{"nctId":"NCT02407704","phase":"PHASE4","title":"A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise","status":"COMPLETED","sponsor":"Kirk Erickson, PhD","startDate":"2015-03","conditions":"Depression, Depressive Disorder, Major, Depressive Disorder","enrollment":31},{"nctId":"NCT00248612","phase":"PHASE2, PHASE3","title":"Psychosocial and Medication Treatment for Anxiety in Alcoholism","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2003-09","conditions":"Alcohol-Related Disorders, Anxiety Disorders","enrollment":162},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT00316160","phase":"PHASE4","title":"Sexual Functioning Study With Antidepressants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-09","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":347},{"nctId":"NCT00620776","phase":"PHASE2","title":"Combined Treatment for Generalized Anxiety Disorder (GAD)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-10","conditions":"Generalized Anxiety Disorder","enrollment":69},{"nctId":"NCT00183274","phase":"PHASE4","title":"Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2004-01","conditions":"Anxiety Disorders","enrollment":268},{"nctId":"NCT00735670","phase":"NA","title":"Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-06","conditions":"Spinal Cord Injury","enrollment":34},{"nctId":"NCT02005107","phase":"PHASE4","title":"Venlafaxine PK Following Bariatric Surgery","status":"COMPLETED","sponsor":"North Dakota State University","startDate":"2013-12","conditions":"Roux en Y Gastric Bypass, Sleeve Gastrectomy","enrollment":12},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT02433353","phase":"PHASE4","title":"Results From a 24 Week Trial of EMDR Combined With Venlafaxine XR","status":"WITHDRAWN","sponsor":"Bayne-Jones Army Community Hospital","startDate":"2016-01","conditions":"Posttraumatic Stress Disorder","enrollment":""},{"nctId":"NCT02086929","phase":"PHASE3","title":"Trazodone Once a Day in Major Depression Disorder","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":364},{"nctId":"NCT01867255","phase":"PHASE1","title":"Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-10","conditions":"Bariatric Surgery, Gastric Bypass, Roux-en-Y Gastric Bypass","enrollment":10},{"nctId":"NCT00892047","phase":"PHASE4","title":"Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2009-08","conditions":"Depression","enrollment":468},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT00179283","phase":"PHASE3","title":"Sertraline vs. Venlafaxine XR","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-04","conditions":"Major Depressive Disorder","enrollment":20},{"nctId":"NCT00253266","phase":"PHASE4","title":"Venlafaxine Augmentation in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Max-Planck-Institute of Psychiatry","startDate":"2008-04","conditions":"Depression","enrollment":126},{"nctId":"NCT00592384","phase":"PHASE4","title":"Project to Improve Symptoms and Mood in People With Spinal Cord Injury","status":"COMPLETED","sponsor":"University of Washington","startDate":"2007-07","conditions":"Major Depressive Disorder, Dysthymia, Spinal Cord Injuries","enrollment":133},{"nctId":"NCT00448058","phase":"PHASE2","title":"A Study Of New Medicine (GSK 372475) For The Treatment Of Depression","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Depressive Disorder","enrollment":396},{"nctId":"NCT01418209","phase":"NA","title":"MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11","conditions":"Hot Flashes, Menopause, Vasomotor Disturbance","enrollment":339},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665},{"nctId":"NCT00167856","phase":"NA","title":"Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-06","conditions":"Neuropathic Pain, Pain, Spinal Cord Injuries","enrollment":16},{"nctId":"NCT00018902","phase":"PHASE2, PHASE3","title":"Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-01","conditions":"Depression","enrollment":334},{"nctId":"NCT00362271","phase":"PHASE1","title":"Aripiprazole and Effexor XR Drug Interaction Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":38},{"nctId":"NCT00177671","phase":"PHASE4","title":"Antidepressant Medication Plus Donepezil for Treating Late-life Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-12","conditions":"Depression, Dementia","enrollment":220},{"nctId":"NCT00086190","phase":"PHASE3","title":"Study of Antidepressants in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-06","conditions":"Parkinson Disease, Depression","enrollment":115},{"nctId":"NCT00083980","phase":"PHASE2","title":"Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)","status":"TERMINATED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2002-06","conditions":"Anxiety Disorders","enrollment":16},{"nctId":"NCT00789854","phase":"PHASE3","title":"Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":688},{"nctId":"NCT00474708","phase":"PHASE4","title":"Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Major Depressive Disorder","enrollment":1151},{"nctId":"NCT01512459","phase":"PHASE1","title":"Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-05","conditions":"Healthy","enrollment":33},{"nctId":"NCT01418625","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01418612","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01282814","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT01282801","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT01260896","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00188643","phase":"PHASE4","title":"Venlafaxine Versus Lamotrigine in the Treatment of Bipolar I/II Depression","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2002-01","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT00195598","phase":"PHASE3","title":"Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-01","conditions":"Panic Disorders","enrollment":70},{"nctId":"NCT00046020","phase":"PHASE4","title":"Study Evaluating Venlafaxine ER in Recurrent Depression","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-08","conditions":"Depressive Disorder, Major, Recurrence","enrollment":1096},{"nctId":"NCT00676039","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2007-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT00177528","phase":"PHASE4","title":"Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2000-10","conditions":"Depression","enrollment":70},{"nctId":"NCT00641927","phase":"PHASE4","title":"Antidepressant Therapy for Bipolar II Major Depression","status":"COMPLETED","sponsor":"Stanley Medical Research Institute","startDate":"2002-04","conditions":"Bipolar Type II Disorder","enrollment":90},{"nctId":"NCT00546923","phase":"PHASE4","title":"Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-08","conditions":"Anxiety Disorders, Depression","enrollment":210},{"nctId":"NCT00225485","phase":"PHASE3","title":"Study Evaluating Effexor XR in Elderly Patients With Major Depression.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-12","conditions":"Depression","enrollment":100},{"nctId":"NCT00225511","phase":"PHASE3","title":"Study Evaluating Effexor XR for Major Depression.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-06","conditions":"Depression","enrollment":590},{"nctId":"NCT00225524","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-09","conditions":"Depression","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":83,"reaction":"DRUG INEFFECTIVE"},{"count":70,"reaction":"DEPRESSION"},{"count":67,"reaction":"NAUSEA"},{"count":66,"reaction":"DIZZINESS"},{"count":64,"reaction":"FATIGUE"},{"count":63,"reaction":"ANXIETY"},{"count":55,"reaction":"DYSPNOEA"},{"count":52,"reaction":"FALL"},{"count":52,"reaction":"OFF LABEL USE"},{"count":51,"reaction":"INSOMNIA"}],"_approvalHistory":[],"publicationCount":256,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Efexor XR","Effexor XR","Escitalopram Oral Tablet","EFFEXOR","Effexor"],"phase":"marketed","status":"active","brandName":"Venlafaxine XR","genericName":"Venlafaxine XR","companyName":"Ministry of Health & Welfare, Korea","companyId":"ministry-of-health-welfare-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}